FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 912-920

  Quinn, Michael C J ^a   Wojnarowicz, Paulina M ^b   Pickett, Amy ^c   Provencher, Diane M ^a,d   Mes Masson, Anne Marie ^a,d   Davis, Elaine C ^c   Tonin, Patricia N ^b,c,e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Chromosome 17; COL1A1; FKBP10; FKBP65; Gene expression; High grade ovarian serous carcinoma; Immunohistochemistry; Tissue microarray

Indexed keywords

CHROMOSOME PROTEIN; COL1A1 PROTEIN; COLLAGEN; FK 506 BINDING PROTEIN; FKBP10 PROTEIN; FKBP65 PROTEIN; IMMUNOPHILIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL COMPONENT; CHROMOSOME 17Q; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PROPERTY; TISSUE MICROARRAY; UTERINE TUBE;

CELL LINE, TUMOR; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; COLLAGEN TYPE I; CYSTADENOCARCINOMA, SEROUS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL; TACROLIMUS BINDING PROTEINS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873679164     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1797     Document Type: Article

References (42)

1. Dion F, Mes-Masson AM, Seymour RJ, Provencher D and Tonin PN: Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Oncogene 19: 1466-1472, 2000. (Pubitemid 30171178)
2. Foulkes WD, Black DM, Stamp GW, Solomon E and Trowsdale J: Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int J Cancer 54: 220-225, 1993. (Pubitemid 23154885)
3. Presneau N, Dewar K, Forgetta V, Provencher D, Mes-Masson AM and Tonin PN: Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog 43: 141-154, 2005. (Pubitemid 40944239)
4. Wojnarowicz PM, Provencher DM, Mes-Masson AM and Tonin PN: Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. Int J Oncol 40: 18656-1880, 2012.
5. TCGA: Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
6. Gorringe KL, George J, Anglesio MS, et al: Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PloS One 5: e11408, 2010.
7. Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE and Turker MS: Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 64: 434-440, 1995. (Pubitemid 26048908)
8. Sangha N, Wu R, Kuick R, et al: Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia 10: 1362-1372, 2008.
9. Feng Q, Deftereos G, Hawes SE, et al: DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. Gynecol Oncol 111: 320-329, 2008.
10. Rathi A, Virmani AK, Schorge JO, et al: Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8: 3324-3331, 2002. (Pubitemid 35340705)
11. Pergolizzi R, Appierto V, Crosti M, et al: Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. Int J Cancer 81: 829-834, 1999. (Pubitemid 29214397)
12. Bruening W, Prowse AH, Schultz DC, Holgado-Madruga M, Wong A and Godwin AK: Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Res 59: 4973-4983, 1999. (Pubitemid 29472903)
13. Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ and Tonin PN: Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene 22: 1568-1579, 2003. (Pubitemid 36390606)
14. Wojnarowicz PM, Breznan A, Arcand SL, et al: Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes. Int J Gynecol Cancer 18: 963-975, 2008.
15. Cody NA, Ouellet V, Manderson EN, et al: Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 26: 618-632, 2007. (Pubitemid 46160975)
16. Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM and Tonin PN: Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Mol Carcinog 48: 648-661, 2009.
17. Coss MC, Winterstein D, Sowder RC II and Simek SL: Molecular cloning, DNA sequence analysis, and biochemical characterization of a novel 65-kDa FK506-binding protein (FKBP65). J Biol Chem 270: 29336-29341, 1995.
18. Zeng B, MacDonald JR, Bann JG, et al: Chicken FK506-binding protein, FKBP65, a member of the FKBP family of peptidylprolyl cis-trans isomerases, is only partially inhibited by FK506. Biochem J 330: 109-114, 1998. (Pubitemid 28076870)
19. Patterson CE, Abrams WR, Wolter NE, Rosenbloom J and Davis EC: Developmental regulation and coordinate reexpression of FKBP65 with extracellular matrix proteins after lung injury suggest a specialized function for this endoplasmic reticulum immunophilin. Cell Stress Chaperones 10: 285-295, 2005. (Pubitemid 41813377)
20. Patterson CE, Schaub T, Coleman EJ and Davis EC: Developmental regulation of FKBP65. An ER-localized extracellular matrix binding-protein. Mol Biol Cell 11: 3925-3935, 2000.
21. Ishikawa Y, Vranka J, Wirz J, Nagata K and Bachinger HP: The rough endoplasmic reticulum-resident FK506-binding protein FKBP65 is a molecular chaperone that interacts with collagens. J Biol Chem 283: 31584-31590, 2008.
22. Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acid Res 39: D945-D950, 2011.
23. Alanay Y, Avaygan H, Camacho N, et al: Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 86: 551-559, 2010.
24. Kelley BP, Malfait F, Bonafe L, et al: Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome. J Bone Miner Res 26: 666-672, 2011.
25. Nishida T, Oda T, Sugiyama T, Izumi S and Yakushiji M: Concurrent ovarian serous carcinoma and osteogenesis imperfecta. Arch Gynecol Obstet 253: 153-156, 1993. (Pubitemid 23282790)
26. Ouellet V, Zietarska M, Portelance L, et al: Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer 8: 152, 2008.
27. Le Page C, Marineau A, Bonza PK, et al: BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PloS One 7: e38541, 2012.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
29. Ouellet V, Provencher DM, Maugard CM, et al: Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 24: 4672-4687, 2005. (Pubitemid 41032604)
30. Rozen S and Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386, 2000.
31. Karolchik D, Baertsch R, Diekhans M, et al: The UCSC Genome Browser Database. Nucleic Acid Res 31: 51-54, 2003. (Pubitemid 36150331)
32. Arcand SL, Maugard CM, Ghadirian P, et al: Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat 108: 399-408, 2008. (Pubitemid 351431072)
33. Davis EC, Broekelmann TJ, Ozawa Y and Mecham RP: Identification of tropoelastin as a ligand for the 65-kD FK506 binding protein, FKBP65, in the secretory pathway. J Cell Biol 140: 295-303, 1998. (Pubitemid 28078393)
34. Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B and Miller D: The fallopian tube: primary site of most pelvic high grade serous carcinomas. Int J Gynecol Cancer 19: 58-64, 2009.
35. Henriksen R, Sorensen FB, Orntoft TF and Birkenkamp-Demtroder K: Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium. Tumour Biol 32: 671-676, 2011.
36. Provencher DM, Lounis H, Champoux L, et al: Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36: 357-361, 2000. (Pubitemid 30626747)
37. Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes Masson AM and Tonin PN: Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog 47: 56-65, 2008.
38. Cody NA, Shen Z, Ripeau JS, et al: Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog 48: 1077-1092, 2009.
39. Manderson EN, Birch AH, Shen Z, Mes-Masson AM, Provencher D and Tonin PN: Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer. Int J Gynecol Cancer 19: 513-525, 2009.
40. Kobel M, Kalloger SE, Boyd N, et al: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232, 2008.
41. Schauer IG, Sood AK, Mok S and Liu J: Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 13: 393-405, 2011.
42. Finak G, Bertos N, Pepin F, et al: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527, 2008. (Pubitemid 351655218)